Published in final edited form as:

Int J Radiat Oncol Biol Phys. 2016 October 1; 96(2): 280–288. doi:10.1016/j.ijrobp.2016.06.009.

Stereotactic Radiosurgery for Brainstem Metastases: An International Cooperative Study to Define Response and Toxicity

Daniel M. Trifiletti, MD^{*}, Cheng-Chia Lee, MD[†], Hideyuki Kano, MD, PhD[‡], Jonathan Cohen[‡], James Janopaul-Naylor[§], Michelle Alonso-Basanta, MD, PhD[§], John Y.K. Lee, MD[§], Gabriela Simonova, MD, PhD^{||}, Roman Liscak, MD, PhD^{||}, Amparo Wolf, MD, PhD[¶], Svetlana Kvint, MD[¶], Inga S. Grills, MD[#], Matthew Johnson, MD[#], Kang-Du Liu, MD[†], Chung-Jung Lin, MD[†], David Mathieu, MD^{**}, France Héroux, MD^{**}, Danilo Silva, MD^{††}, Mayur Sharma, MD^{††}, Christopher P. Cifarelli, MD, PhD^{‡‡}, Christopher N. Watson, MD^{‡‡}, Joshua D. Hack, MS^{‡‡}, John G. Golfinos, MD[¶], Douglas Kondziolka, MD, MSc[¶], Gene Barnett, MD, MBA^{††}, L. Dade Lunsford, MD[‡], and Jason P. Sheehan, MD, PhD^{*,§§}

^{*}Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia

[†]Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan, People's Republic of China

[‡]Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

[§]Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania

^{||}Department of Radiation and Stereotactic Neurosurgery, Na Homolce Hospital, Prague, Czech Republic

[¶]Department of Neurosurgery, New York University Lagone Medical Center, New York, New York

[#]Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan

^{**}Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada

^{††}Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio

^{‡‡}Departments of Neurosurgery and Radiation Oncology, West Virginia University, Morgantown, West Virginia

^{§§}Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia

Abstract

Purpose—To pool data across multiple institutions internationally and report on the cumulative experience of brainstem stereotactic radiosurgery (SRS).

Reprint requests to: Daniel M. Trifiletti, MD, Department of Radiation Oncology, University of Virginia Health System, 1240 Lee St, Box 800383, Charlottesville, VA 22908. Tel: (434) 982-6278; daniel.trifiletti@gmail.com.

Conflict of interest: I.S.G. has stock interests and is on the Board of Directors for Greater Michigan Gamma Knife; and has an institutional research grant held with Elekta as part of the Elekta Collaborative Lung Research Group and is the Principle investigator. R.L. is a consultant for Elekta. L.D.L. is a consultant for and shareholder in Elekta.

Methods and Materials—Data on patients with brainstem metastases treated with SRS were collected through the International Gamma Knife Research Foundation. Clinical, radiographic, and dosimetric characteristics were compared for factors prognostic for local control (LC) and overall survival (OS) using univariate and multivariate analyses.

Results—Of 547 patients with 596 brainstem metastases treated with SRS, treatment of 7.4% of tumors resulted in severe SRS-induced toxicity (grade 3, increased odds with increasing tumor volume, margin dose, and whole-brain irradiation). Local control at 12 months after SRS was 81.8% and was improved with increasing margin dose and maximum dose. Overall survival at 12 months after SRS was 32.7% and impacted by age, gender, number of metastases, tumor histology, and performance score.

Conclusions—Our study provides additional evidence that SRS has become an option for patients with brainstem metastases, with an excellent benefit-to-risk ratio in the hands of experienced clinicians. Prior whole-brain irradiation increases the risk of severe toxicity in brainstem metastasis patients undergoing SRS.

Introduction

Stereotactic radiosurgery (SRS) has repeatedly demonstrated its safety and effectiveness when used to treat patients with brain metastases (1-3). As a result of several large trials, SRS has gained popularity by demonstrating excellent local control and uncommon toxicity (4).

One caveat is that the studies validating SRS (5-7), as well as recent protocols (8), did not include patients with tumors involving or abutting the brainstem (ie, the midbrain, pons, and medulla oblongata). This is based on concerns that SRS dose, even at the tumor margin, exceeds brainstem goal dose tolerance for a single fraction and that SRS-induced injury to this location could be severe and potentially life-threatening (9, 10).

Metastatic tumors within the brainstem pose many unique and difficult therapy decisions. Local progression of disease within the brainstem is associated with an acute and severe neurologic decline. Access by craniotomy is not indicated because of the risk associated with the approach corridors needed to resect the metastasis even if it is exophytic. Systemic chemotherapy has little demonstrated effectiveness.

Several small, single-institution series have reported the outcomes of brainstem SRS, usually with fewer than 60 patients included (11-19). Early studies had limited ability to draw conclusions because of their small sample size and heterogeneity across patients. Moreover, some reports have established conflicting recommendations regarding several prognostic factors, including optimum SRS margin dose (17, 18, 20-22).

Our proposed aims include to: (1) define the safety of SRS for brainstem metastases; (2) define the efficacy of SRS for brainstem metastases; and (3) evaluate clinical and treatment factors that might affect survival after radiosurgery.

Methods and Materials

Data collection

We proposed the following analysis to the International Gamma Knife Research Foundation. After approval by the steering committee all participating institutions were invited to provide their deidentified institutional data of all patients treated with SRS for brainstem metastases at their institution with follow-up data available. Patients with brainstem metastases diagnosed at initial cancer presentation or anytime thereafter were included. Clinical data collection included age, gender, Karnofsky performance score, tumor histology (as determined by the primary site), time from primary diagnosis to SRS, total intracranial metastases, active extracranial disease presence and location, whole-brain radiation therapy (WBRT) dose and timing, and chemotherapy use before SRS. Tumor location was divided into midbrain, pons, medulla oblongata, or overlapping. Tumors of the cerebellopontine angle were included when the tumor invaded the brainstem proper, resulting in at least prescription dose to the brainstem parenchyma. Patients without radiographic or clinical follow-up were excluded. Collection and sharing of data was approved through each participating center's institutional review board.

The SRS parameters included brainstem tumor volume, margin dose, isodose, and maximum dose. Follow-up data collected included radiographic local control and evidence of severe clinical toxicity (grade 3 according to the Common Terminology Criteria for Adverse Events, version 4.03) (23), and overall survival after brainstem SRS. To allow for subtle differences in MRI technique and patient positioning, tumor volume changes of 10% or less from baseline were termed unchanged in size (24).

Statistical analysis

Tumors were said to be controlled locally if they were decreased or unchanged in size, and to have failed locally if they increased in size (as determined by a volume increase of >10%) over the follow-up period (24). Collected data were analyzed via Kaplan-Meier plots of overall and progression-free survival after SRS. Log-rank tests were used to investigate possible differences between these curves after stratification by various prognostic factors. Potential prognostic factors were analyzed for an association with clinical outcomes via univariate and multivariate logistic and/or Cox regression analysis. Differences were considered statistically significant if $P < .05$, and statistics were calculated using commercially available statistics software (SPSS version 20.0; SPSS, Chicago, IL).

Participating centers

Ten centers from 4 countries provided data meeting inclusion criteria on 547 patients with 596 brainstem tumors treated with Gamma Knife SRS (Elekta AB, Stockholm, Sweden). Table 1 provides the clinical characteristics of the patients included in our series. The median age of patients at the time of SRS was 61 years. Twenty-six percent underwent SRS for a single brain metastasis located in the brainstem; 76% had additional brain lesions (16% with 1 other lesion, 11% with 2 other lesions, and 48% with >2 other lesions). Brainstem tumor volume varied from 0.01 mL to 21 mL (median 0.8 mL). Forty-nine percent of patients underwent WBRT before brainstem SRS. Although SRS prescription dose varied

between patients and institutions, the median dose was 16 Gy prescribed to the 50% isodose line and a median maximum dose of 30 Gy.

Results

Local tumor control

Local tumor control (brainstem tumors only) among all patients in the series is depicted in Figure 1. At 1 year after brainstem SRS, local control was 81.8%. Table 2 provides an analysis of factors associated with increased risk of local tumor failure. As demonstrated, age, margin dose of <16 Gy (compared with margin dose of ≥20 Gy), and maximum dose were the only factors associated with increased risk of local failure on multivariate analysis ($P=.007$, $P=.039$, and $P=.020$, respectively). The multivariate analysis of local failure was reanalyzed using margin dose as a continuous variable, and increased margin dose trended toward, but did not meet, statistical significance (hazard ratio 0.572, $P=.091$). When stratifying according to the receipt of WBRT, there was no difference in margin dose selection or ultimate brainstem local control ($P=.405$ and $.686$, respectively). Tumor histology did not impact the rate of local failure (Table 2). Figure 2 (right) displays the ranges of margin doses used in patients stratified by whether they went on to develop local tumor control after SRS.

Overall survival

Figure 1 demonstrates the overall survival of all patients after brainstem SRS, as well as overall survival among patients stratified by age. Median survival was 5.6 months, and the 1-year survival was 32.7%. The 2-year survival was 16.7%, and 10.9% of patients remained alive 3 years after brainstem SRS. A total of 143 patients died of systemic disease progression (26%), 88 patients died of non-brainstem intracranial disease progression (16%), 4 died of brainstem disease progression (0.7%), and the cause of death could not be determined in 312 (57%).

Table 3 provides an analysis of factors prognostic for overall survival. As demonstrated, several factors were associated with longer survival, including younger age, single metastases (brainstem metastasis—only patients), and non-melanoma histology ($P<.001$, $P<.001$, and $P=.039$, respectively) favorably impacting overall survival.

Radiation toxicity

Severe toxicity after brainstem SRS was rare. It was defined by established criteria. We used the following grading: severe (grade ≥3) toxicity was defined as local edema, hemorrhage, or radionecrosis requiring intervention (medical or surgical), or any treatment-related death (grade 5). Severe toxicity also included any neuropathy, encephalopathy, seizure, syncope, memory loss, or ataxia with severe symptoms limiting activities of daily living. Forty-four patients (7.4%) developed a grade 3 to 4 toxicity as a result of brainstem SRS at any time point in follow-up. There were 2 grade 4 toxicities (0.3%; intrapontine hemorrhage and hemibody paralysis); the remaining toxicities were grade 3 or less (severe extremity motor weakness in 5 patients, severe ataxia in 3 patients, cranial nerve paralysis in 2 patients,

severe headaches in 1 patient, otherwise grade 3 with unknown details). There were no neurologic deaths attributable to brainstem SRS (0%).

Of the 266 patients (48.6%) who received WBRT before brainstem SRS, the median interval between WBRT and SRS was 4.5 months (range 0-46.1 months). Of the 44 patients who developed a severe toxicity, 84% had undergone WBRT before brainstem SRS (compared with 47% in the subgroup that did not go on to develop a severe toxicity, $P<.001$). Among patients who received prior WBRT, an increased interval from WBRT to brainstem SRS was also found to predict for decreased risk of radiation toxicity (odds ratio 0.116 for 4.5 months compared with <4.5 months, $P<.001$). The median WBRT total dose was 30 Gy (range, 20-57.5 Gy). No severe toxicity was noted in brainstem tumors smaller than 0.1 mL or in tumors treated to a margin dose of <12 Gy. There was no effect of brainstem tumor location or volume of tissue receiving 12 Gy (V12) on severe toxicity ($P=.30$ and $.06$, respectively).

Table 4 provides an analysis of factors associated with increased odds of a severe toxicity. As demonstrated, increasing tumor volume, increasing margin dose, and pre-SRS WBRT were each associated with increased odds of severe toxicity after SRS ($P<.001$, $P=.049$, and $P=.002$, respectively). Figure 2 (left) displays the ranges of margin doses used in patients stratified by whether they went on to develop a severe SRS toxicity.

Discussion

The therapeutic window

In the largest series reported on the topic, our results support SRS as an effective treatment option for many patients with brainstem metastases. Unlike other locations within the brain, brainstem metastases are seldom resected given the surgical risks associated with their location in regions of critical brain function. Before the widespread use of SRS, WBRT was the only palliative treatment option (25). We found that SRS provided a generally low risk of toxicity and a favorable rate of local control. Our results are novel for several reasons. First, they evaluated a large series of patients treated across a variety of institutions. Second, our results demonstrate the increased risk of toxicity with brainstem SRS after WBRT, and that this risk is lessened with increased interval from WBRT to SRS. Third, our results provide data on the therapeutic ratio of radiosurgery (a dose-response and dose-toxicity relationship), and this can assist the development of clinically appropriate dose guidelines for patients with brainstem metastases treated with SRS.

Tumor margin dose selection is particularly important in patients with brainstem metastases because the tissue just outside of the tumor often serves important neurologic functions. Poor selectivity of the radiation dose beyond the tumor margin can lead to an increased risk of radiation-related neurologic toxicity. The literature notes conflicting recommendations regarding the optimum margin dose to maximize the therapeutic ratio (17, 18, 20, 21). Although some small series demonstrated improve local control with the use of doses of at least 15 to 20 Gy (20-22), other series recommend tumor margin doses as low as 12 Gy (18, 26). Additionally, the radiosurgical technology used may affect the rate of fall-off of radiation beyond the tumor margin and impact toxicity rate. Although the impact of

hypofractionated radiosurgery on brainstem metastasis local control and toxicity is unknown, it has the potential to further improve the therapeutic ratio in selected patients.

Edema, hemorrhage, or radionecrosis in the brainstem after SRS can clinically manifest as cranial nerve deficits, hemiplegia, loss of consciousness, or death. This realization has led some to use lower doses that are potentially ineffective for tumor control. Some reports of severe toxicity after brainstem SRS margin doses >16 Gy have led some authors to recommend avoiding doses this high(18, 26). Because of the small sample sizes, there was limited statistical power to associate SRS brainstem toxicity with tumor volume, location, margin dose, or previous WBRT. As a result, a dose threshold, volume threshold, or other prognostic factor that can estimate radiation-related toxicity was not developed. Although the existing studies demonstrated statistically significant results and recommendations regarding brainstem SRS, other reports have failed to demonstrate a dose-response relationship (11-18, 27-30).

Dose optimization

Our results demonstrate that, depending on tumor volume, margin doses in the 16- to 24-Gy range may provide an appropriate balance of the risks of severe toxicity while maintaining tumor control (Fig. 2 and Tables 2 and 4). We found that prior WBRT significantly increased the risk of delayed severe radiation-related toxicity. If WBRT has already been administered and SRS is required to gain tumor control, a further reduction in the SRS tumor margin dose may be needed. In the present study we did not find that the 12-Gy volume (which includes the tumor and the surrounding brain outside of the tumor margin) was associated with detection of delayed toxicity. This is perhaps because of the smaller anatomic volume of the brainstem and tendency for brainstem metastases themselves to be smaller at the time of recognition. In this study we found that the median survival was 5.6 months, and the 1-year survival was 32.7%. The 2-year survival was 16.7%.

We believe that this analysis confirms that SRS is an ideal option for patients with brainstem metastases otherwise eligible for SRS. Although metastatic disease in the brainstem in the past has portended a generally poor prognosis (31), future advances in systemic therapies, including targeted and immune therapies, may improve systemic control, and the development of novel radio-sensitizers or radio-protectors may further change the effective dose that SRS can provide.

Study limitations

These data were obtained through a retrospective chart review of prospectively collected data. Although a phase 3 randomized trial that evaluates efficacy and toxicity in this patient population would be desirable, such a study is unlikely. The present study is a retrospective analysis of a heterogeneous patient population, and it is possible that other unmeasured confounding variables may affect our results. For example, targetable genetic mutations, and associated other medical comorbidities, may influence both local and systemic disease control. Likewise, steroid therapy concurrent with SRS may impact radiation-induced toxicity. On the basis of the presented survival data, follow-up time is generally limited in this patient population, and it is possible that our reported toxicity rate may increase in the

small volume of long-term survivors. It is noteworthy that survival was measured from the time of brainstem SRS. This means that some patients had already survived months (or years) after their initial systemic cancer or brain metastasis presentation. However, to inform on survival of these patients in a practical way that could be extended to patients in clinic, we limited survival analyses to the methods described.

All patients in this series underwent Gamma Knife SRS at centers with extensive SRS expertise. Brainstem SRS using other treatment platforms is not described here, but can likely be extrapolated to other validated platforms where appropriate.

Conclusion

This study supports our view that SRS delivered at centers with advanced technology and experienced practitioners is an appropriate treatment option for patients with brainstem metastases. It provides favorable local control and relatively rare toxicity. In the setting of brainstem SRS after WBRT, particularly when a short interval exists between the two (ie, <4.5 months), dose reduction should be considered to lessen the risk of adverse radiation effects. Further study through prospective trials and clinical registries can be performed to ascertain the generalizability of the present findings.

References

1. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. *Lancet*. 2004; 363:1665–1672. [PubMed: 15158627]
2. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. *Lancet Oncol*. 2009; 10:1037–1044. [PubMed: 19801201]
3. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med*. 1990; 322:494–500. [PubMed: 2405271]
4. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010; 96:45–68. [PubMed: 19960227]
5. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. *Int J Radiat Oncol Biol Phys*. 2000; 47:291–298. [PubMed: 10802351]
6. O'Neill BP, Iturria NJ, Link MJ, et al. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. *Int J Radiat Oncol Biol Phys*. 2003; 55:1169–1176. [PubMed: 12654423]
7. Kocher M, Soffiotti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. *J Clin Oncol*. 2011; 29:134–141. [PubMed: 21041710]
8. Brown, PD. [Accessed February 19, 2015] N0574: Stereotactic radiation therapy with or without whole-brain radiation therapy in treating patients with brain metastases. Available at: <http://meetinglibrary.asco.org/content/146056-156>
9. Sharma MS, Kondziolka D, Khan A, et al. Radiation tolerance limits of the brainstem. *Neurosurgery*. 2008; 63:728–732. [discussion 732-723]. [PubMed: 18981883]
10. Mayo C, Yorke E, Merchant TE. Radiation associated brainstem injury. *Int J Radiat Oncol Biol Phys*. 2010; 76:S36–S41. [PubMed: 20171516]
11. Kased N, Huang K, Nakamura JL, et al. Gamma knife radiosurgery for brainstem metastases: The UCSF experience. *J Neurooncol*. 2008; 86:195–205. [PubMed: 17628747]

12. Koyfman SA, Tendulkar RD, Chao ST, et al. Stereotactic radiosurgery for single brainstem metastases: The Cleveland Clinic experience. *Int J Radiat Oncol Biol Phys.* 2010; 78:409–414. [PubMed: 20133072]
13. Hatiboglu MA, Chang EL, Suki D, et al. Outcomes and prognostic factors for patients with brainstem metastases undergoing stereotactic radiosurgery. *Neurosurgery.* 2011; 69:796–806. [discussion 806]. [PubMed: 21508879]
14. Kawabe T, Yamamoto M, Sato Y, et al. Gamma Knife surgery for patients with brainstem metastases. *J Neurosurg.* 2012; 117(Suppl.):23–30. [PubMed: 23205785]
15. Sengoz M, Kabalay IA, Tezcanli E, et al. Treatment of brainstem metastases with gamma-knife radiosurgery. *J Neurooncol.* 2013; 113:33–38. [PubMed: 23443514]
16. Peterson HE, Larson EW, Fairbanks RK, et al. Gamma knife treatment of brainstem metastases. *Int J Mol Sci.* 2014; 15:9748–9761. [PubMed: 24886816]
17. Kilburn JM, Ellis TL, Lovato JF, et al. Local control and toxicity outcomes in brainstem metastases treated with single fraction radiosurgery: Is there a volume threshold for toxicity? *J Neurooncol.* 2014; 117:167–174. [PubMed: 24504497]
18. Lin CS, Selch MT, Lee SP, et al. Accelerator-based stereotactic radiosurgery for brainstem metastases. *Neurosurgery.* 2012; 70:953–958. [discussion 958]. [PubMed: 21997541]
19. Yen CP, Sheehan J, Patterson G, et al. Gamma knife surgery for metastatic brainstem tumors. *J Neurosurg.* 2006; 105:213–219. [PubMed: 17219825]
20. Lorenzoni JG, Devriendt D, Massager N, et al. Brain stem metastases treated with radiosurgery: Prognostic factors of survival and life expectancy estimation. *Surg Neurol.* 2009; 71:188–195. [discussion 195–186]. [PubMed: 18439658]
21. Leeman JE, Clump DA, Wegner RE, et al. Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases. *Radiat Oncol.* 2012; 7:107. [PubMed: 22784482]
22. Shuto T, Fujino H, Asada H, et al. Gamma knife radiosurgery for metastatic tumours in the brain stem. *Acta Neurochir (Wien).* 2003; 145:755–760. [PubMed: 14505101]
23. National Institutes of Health. National Cancer Institute. [Accessed July 22, 2015] Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
24. Snell JW, Sheehan J, Stroiila M, et al. Assessment of imaging studies used with radiosurgery: A volumetric algorithm and an estimation of its error. Technical note. *J Neurosurg.* 2006; 104:157–162. [PubMed: 16509161]
25. Bhatnagar AK, Flickinger JC, Kondziolka D, et al. Stereotactic radiosurgery for four or more intracranial metastases. *Int J Radiat Oncol Biol Phys.* 2006; 64:898–903. [PubMed: 16338097]
26. Valery CA, Boskos C, Boissarie G, et al. Minimized doses for linear accelerator radiosurgery of brainstem metastasis. *Int J Radiat Oncol Biol Phys.* 2011; 80:362–368. [PubMed: 20598449]
27. Huang CF, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for brainstem metastases. *J Neurosurg.* 1999; 91:563–568. [PubMed: 10507375]
28. Yoo TW, Park ES, Kwon do H, et al. Gamma knife radiosurgery for brainstem metastasis. *J Korean Neurosurg Soc.* 2011; 50:299–303. [PubMed: 22200010]
29. Kelly PJ, Lin YB, Yu AY, et al. Linear accelerator-based stereotactic radiosurgery for brainstem metastases: The Dana-Farber/Brigham and Women's Cancer Center experience. *J Neurooncol.* 2011; 104:553–557. [PubMed: 21213018]
30. Jung EW, Rakowski JT, Delly F, et al. Gamma Knife radiosurgery in the management of brainstem metastases. *Clin Neurol Neurosurg.* 2013; 115:2023–2028. [PubMed: 23870233]
31. Trifiletti DM, Lee CC, Shah N, et al. How does brainstem involvement affect prognosis in patients with limited brain metastases? Results of a matched-cohort analysis. *World Neurosurg.* 2016; 88:563–568. [PubMed: 26555507]

Summary

Stereotactic radiosurgery (SRS) within the brainstem exceeds historically identified dose tolerance guidelines. In the largest series to be reported, our results demonstrate that SRS for brainstem metastases resulted in a local control rate of 82% at 1 year and an overall severe toxicity rate of 7.4%. Margin doses of at least 20 Gy were associated with improved local control but increased toxicity.

Fig. 1.

Kaplan-Meier curves for local tumor control among all tumors (upper left) and among tumors stratified by margin dose (upper right, P values compare with 20-Gy margin dose), as well as for overall survival after brainstem stereotactic radiosurgery among all patients (lower left) and among patients stratified by age (lower right).

Fig. 2.

Ranges of margin doses used in patients stratified by whether they went on to develop severe toxicity (left) and local tumor control (right) after stereotactic radiosurgery.

Table 1

Clinical characteristics of 596 brainstem metastatic tumors in 547 patients

Characteristic	Value	Percentage or range
Sex (male:female)	266:281	
Median age (y)	61	23-96
Brainstem tumor size (mL)	0.8	0.01-21.0
Total intracranial metastases (n=547)		
1 (single lesion)	142	26
2	85	16
3	58	11
>3	253	48
Location of tumor (n=596)		
Midbrain	126	21
Pons	345	58
Medulla	45	8
CP angle	14	2
Midbrain-pons	44	7
Pons-medulla	22	4
KPS (median)	90	30-100
Extracranial metastasis (n=547)		
Yes	370	68
No	177	32
Primary tumor (n=547)		
NSCLC	227	41
Breast cancer	140	26
Melanoma	75	14
Renal cell	58	11
GI tract origin	17	3
SCLC	16	3
Other *	7	1
Unknown	7	1
Neurologic symptoms/signs (n=547, may be multiple)		
Long tract signs	281	51
Cerebellar signs	75	14
Cranial nerve palsy	151	28
Asymptomatic	179	33
Median image follow-up (mo)	5.5	0.1-244
Median clinical follow-up (mo)	5.6	0.1-237
Prior WBRT (n=547)	266	49

Characteristic	Value	Percentage or range
Prior chemotherapy (nZ547)	412	75
SRS [†]		
Margin dose (Gy)	16	8-25
Isodose level (%)	50	26-98
Maximum dose (Gy)	30	13-67
Median survival (mo)	5.6	0.1-237

Abbreviations: CP = cerebellopontine; GI = gastrointestinal; KPS = Karnofsky performance status; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; SRS = stereotactic radiosurgery; WBRT = whole-brain radiation therapy.

* “Other” includes bladder cancer, lymphoma, oral cavity cancer, malignant peripheral nerve sheath tumor, nasopharyngeal cancer, Ewing’s sarcoma, salivary gland cancer, skin cancer, thyroid cancer, fibrohistiocytoma, and carcinoma of unknown origin.

[†] Parameters of SRS are reported as median values for each brainstem metastasis, not the entire treatment volume.

Table 2

Prognostic factors associated with local failure in 596 brainstem metastases (presented by Cox regression)

Factor	n	Univariate			Multivariate		
		P	Hazard ratio *	95% CI	P	Hazard ratio *	95% CI
Age (y)		.090			.007		
<65	366		Ref			Ref	
65	230		1.588	0.930-2.711		2.377	1.261-4.482
Gender		.064			.575		
Male	286		Ref			Ref	
Female	310		0.607	0.358-1.029		0.815	0.398-1.668
No. of lesions		.694					
Single	142		Ref				
Multiple	454		0.896	0.517-1.551			
Active systemic metastases		.035			.143		
No	197		Ref			Ref	
Yes	399		1.957	1.049-3.653		1.683	0.838-3.380
Tumor volume (mL)		.482					
<1	271		Ref				
1-2	68	.283	1.551	0.696-3.458			
>2	201	.376	1.308	0.722-2.369			
Primary tumory [†]		.076			.568		
Breast cancer	159		Ref			Ref	
NSCLC	246	.212	1.642	0.754-3.576	.756	1.155	0.466-2.859
SCLC	16	.984	1.034	0.812-1.188	.985	1.036	0.814-1.189
RCC	60	.498	1.431	0.507-4.035	.954	0.964	0.279-3.338
Melanoma	84	.003	3.881	1.599-9.417	.135	2.450	0.757-7.926
GI tract origin	17	.983	1.022	0.972-1.029	.985	1.031	0.988-1.021
Tumor location		.591					
Midbrain	126		Ref				
Pons	345	.416	0.491	0.088-2.725			
Medulla	45	.718	0.858	0.373-1.972			
CP angle	14	.256	1.465	0.758-2.832			
Midbrain-pons	44	.994	1.005	0.332-3.043			
Pons-medulla	22	.728	0.738	0.133-4.095			
Margin dose (Gy)		.110			.096		
<16	172		Ref			Ref	
16-19.9	319	.061	0.496	0.238-1.032	.809	0.883	0.322-2.422
20	105	.074	0.562	0.298-1.058	.043	0.478	0.234-0.977
Maximum dose (Gy)		.036			.039		
<32	300		Ref			Ref	
32-40	211	.073	0.469	0.205-1.073	.020	0.290	0.102-0.823
>40	85	.966	0.983	0.442-2.185	.389	0.660	0.256-1.700

Factor	n	Univariate			Multivariate		
		P	Hazard ratio [*]	95% CI	P	Hazard ratio [*]	95% CI
Prior WBRT		.686					
No	301		Ref				
Yes	295		1.124	0.639-1.977			
Prior chemotherapy		.995					
No	155		Ref				
Yes	441		1.002	0.570-1.760			

Abbreviation: CI = confidence interval. Other abbreviations as in Table 1.

^{*} Higher hazard ratio, higher relative risk to local treatment failure.

[†] Excludes unknown and other primary histology.

Table 3

Prognostic factors associated with overall survival in 547 patients with brainstem metastases (presented by Cox regression)

Factor	n	Univariate			Multivariate		
		P	Hazard ratio *	95% CI	P	Hazard ratio *	95% CI
Age (y)		.002			<.001		
<65	346		Ref			Ref	
65	201		1.363	1.122-1.675		1.573	1.258-1.966
Gender		<.001			.031		
Male	266		Ref			Ref	
Female	281		0.704	0.584-0.849		0.769	0.605-0.976
No. of lesions		.003			<.001		
Single	142		Ref			Ref	
Multiple	405		1.400	1.124-1.744		1.636	1.274-2.099
Extracranial metastasis		.024			.059		
No	177		Ref			Ref	
Yes	370		1.264	1.031-1.548		1.237	0.992-1.542
Total tumor volume (mL)		.917					
<1	251		Ref				
1-2	59	.820	1.036	0.763-1.408			
>2	181	.788	0.972	0.791-1.195			
Primary tumor †		.007			.022		
Breast cancer	140		Ref			Ref	
NSCLC	227	.286	1.146	0.892-1.471	.610	0.928	0.695-1.238
SCLC	16	.811	0.916	0.445-1.884	.557	0.801	0.383-1.678
RCC	58	.540	1.113	0.790-1.568	.347	0.826	0.554-1.231
Melanoma	75	<.001	1.825	1.335-2.496	.039	1.473	1.020-2.126
GI origin	17	.858	1.061	0.553-2.036	.219	0.645	0.320-1.299
KPS	547	<.001	0.979	0.972-0.986	<.001	0.971	0.962-0.979
Margin dose (Gy)		.135			.235		
<16	156		Ref			Ref	
16-19.9	289	.088	1.215	0.971-1.520	.170	1.192	0.927-1.532
20	102	.072	1.299	0.977-1.726	.105	1.311	0.945-1.820
Maximum dose (Gy)		.539					
<32	274		Ref				
32-40	198	.270	1.120	0.916-1.370			
>40	75	.857	1.031	0.744-1.428			
Prior WBRT		.185					
No	281		Ref				
Yes	266		1.136	0.941-1.371			
Prior chemotherapy		.718					
No	135		Ref				

Factor	n	Univariate			Multivariate		
		P	Hazard ratio [*]	95% CI	P	Hazard ratio [*]	95% CI
Yes	412		1.037	0.851-1.263			

Abbreviations as in Tables 1 and 2.

^{*} Higher hazard ratio, higher relative risk of death.

[†] Excludes unknown and other primary histology.

Table 4

Prognostic factors associated with severe radiation toxicity in 596 brainstem metastases (presented by logistic regression)

Factor	n	Univariate			Multivariate		
		P	Odds ratio	95% CI	P	Odds ratio	95% CI
Age (y)		.900					
<65	366		Ref				
65	230		0.960	0.507-1.817			
Gender		.172					
Male	286		Ref				
Female	310		0.651	0.351-1.205			
Tumor volume (mL)		<.001			<.001		
<1	271		Ref			Ref	
1-2	68	<.001	12.842	4.357-37.851	<.001	14.407	4.355-47.662
>2	201	<.001	9.992	3.751-26.246	<.001	11.736	3.876-35.540
Primary tumor *		.008			.606		
Breast cancer	159		Ref			Ref	
NSCLC	246	.352	1.438	0.621-3.808	.640	1.269	0.467-3.452
SCLC	16	.830	1.267	0.146-11.008	.463	2.522	0.214-29.775
RCC	60	.002	4.957	1.841-13.347	.446	1.545	0.505-4.730
Melanoma	84	.423	0.521	0.105-2.571	.255	0.374	0.069-2.035
GI origin	17	.830	1.267	0.146-11.008	.967	0.951	0.089-10.114
Margin dose *(Gy)		.012			.049		
<16	172		Ref			Ref	
16-19.9	319	.009	3.654	1.386-9.634	.041	3.786	1.054-13.598
20	105	.004	4.998	1.682-14.848	.015	5.787	1.416-23.653
Maximum dose (Gy)		<.001			.956		
<32	300		Ref			Ref	
32-40	211	<.001	4.921	2.352-10.295	.949	0.966	0.335-2.783
>40	85	.105	2.696	0.812-8.951	.778	0.811	0.190-3.472
Prior WBRT		<.001			.002		
No	301		Ref			Ref	
Yes	295		4.688	2.055-10.698		4.488	1.768-11.396
Prior chemotherapy		.393					
No	155		Ref				
Yes	441		0.757	0.399-1.436			

Abbreviations as in Tables 1 and 2.

Grade 3 to 4 toxicity (n=44) compared with grade 0 to 2 toxicity (n=552), no grade 5 toxicity was reported.

* Excludes unknown and other primary histology.